linjc16/ctgov huggingface dataset:
Intimate Partner Violence as a Risk Factor for Venous Thromboembolism in Women

Study Overview
=================
Brief Summary
-----------------
The frequency of violence against women, or intimate partner violence (IPV) is more and more underlined and recognized as a cofactor favoring certain somatic and psychic pathologies. However, its incidence in patients with venous thromboembolism (VTE) is unknown and its status as a risk factor is still elusive and ambiguous. Investigators therefore conducted a matched case-control study consisting of women taking combined oral contraceptives (COC) who were investigated and followed up between 2010 and 2020. The cases are the patients investigated for their first venous thromboembolic event, The controls were women free of thrombosis who had regular gynecological checkups. Case-control pairs were matched on region of residence, age (+/- 2 years), duration of COC intake (+/- 4 months), COC type (2nd, 3rd or 4th generation).

Official Title
-----------------
(WAST-VTE) Intimate Partner Violence as a Risk Factor for Venous Thromboembolism in Women on Combined Oral Contraceptives: a Matched Case-control Study

Conditions
-----------------
Venous Thrombosis

Intervention / Treatment
-----------------
* Other: WAST questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients: first venous thromboembolic event associated with the intake of combined oral contraceptives Controls: regular follow-up of their combined oral contraception Patient-Control pairs matched on region of residence, age, duration of COC intake, type of COC.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>First venous thromboembolic event associated with combined oral contraceptives intake | Other: WAST questionnaire<br>* WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence. (ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)<br>|
| Controls<br>regular follow-up of their combined oral contraception | Other: WAST questionnaire<br>* WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence. (ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Woman Abuse Screening Tool (WAST) | Self-administered questionnaire | inclusion |
Impact of Alpha Lipoic Acid Efficacy in Burning Mouth Syndrome

Study Overview
=================
Brief Summary
-----------------
A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of alpha lipoic acid (ALA) and determine the statistical significance of the outcome variables. Burning mouth syndrome (BMS) is defined as an oral burning sensation in the absence of clinical signs which could justify the syndrome. Recent studies suggest the existence of neurological factors as a possible cause of the disease.

Detailed Description
-----------------
A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of alpha lipoic acid (ALA) and determine the statistical significance of the outcome variables. 60 patients with BMS, in two groups: case group with 600 mg/day and placebo as control group; with a follow-up of 2 months.

Official Title
-----------------
Impact of Alpha Lipoic Acid Efficacy in Burning Mouth Syndrome Using a Topical Gel

Conditions
-----------------
Burning Mouth Syndrome

Intervention / Treatment
-----------------
* Other: Lipoid acid gel
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with no clinical signs that could justify the syndrome Exclusion Criteria: clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with no clinical signs that could justify the syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: The main objective of this study was to evaluate the efficacy of lipoic acid over placebo in the management of BMS
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lipoic acid gel<br>Patients were treated with a topic gel of lipoic acid | Other: Lipoid acid gel<br>* Topic lipoid acid gel used with topic oral gel used on tongue<br>|
| Placebo Comparator: Placebo<br>Patients treated with a placebo gel control | Drug: Placebo<br>* Placebo oral gel used on tongue<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evolution of burning mouth | Evolution of burning mouth symptoms change through a questionnaire | 6 months |
Sexual Dysfunction After Renal Transplantation

Study Overview
=================
Brief Summary
-----------------
A questionnaire will be send to kidney transplant recipients to investigate characteristics of them and their sexual function, all participants in the survey are anonymous and voluntary, then analyse these characteristics.

Official Title
-----------------
Sexual Function and Reproductive Function of Kidney Transplant Recipients

Conditions
-----------------
Sexual Dysfunction

Intervention / Treatment
-----------------
* Other: no Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who have undergone kidney transplantation for more than six months Exclusion Criteria: having no sexual partner, being under 18 or over 70 years of age, exhibiting abnormal mental behavior, having poor understanding and communication ability, having low intelligence, or having a congenital sexual disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Renal transplant group<br> | Other: no Intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of participants is up to 500 |  | 2024.06 |
Intraligamental Local Anesthesia Versus Infiltration Technique for Extraction of Grade II Mobility Maxillary Molars

Study Overview
=================
Brief Summary
-----------------
The study aims to assess the use of intraligamental local anesthetic injection compared to buccal infiltration for extraction of maxillary molars suffering grade II mobility in terms of pain control and extraction duration.

Official Title
-----------------
Efficacy of Low Dose Intraligamental Local Anesthesia as an Alternative for Infiltration Technique for Extraction of Grade II Mobility Maxillary Molars: Double Blind Randomized Clinical Trial

Conditions
-----------------
Anesthesia, Local

Intervention / Treatment
-----------------
* Procedure: Intraligamental local anesthetic injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy patients (class I category according to American society of anesthesiologists ) Age range: 20 - 60 years of age, Either genders who are seeking dental extraction of maxillary molar teeth diagnosed with grade II mobility. Exclusion Criteria: Patients with tooth that require trans osseous extraction Badly broken down coronal structure of the tooth to be extracted Patients with significant medical conditions Alcoh intake Patients on drugs that affect the central nervous systems Patients who reported the use of drugs that might interfere with pain sensitivity Pregnant or lactating women Patients who suffer from hypersensitivity to local anesthetics or non-steroidal anti-inflammatory drugs (NSAIDs).

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intraligamental local anesthetic injection<br> | Procedure: Intraligamental local anesthetic injection<br>* The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)<br>|
| No Intervention: Buccal infiltration local anesthetic injection<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain using visual analogue scale | visual analogue scale (VAS) was used in which a pain score was recorded for each patient just after local anesthetic adminstration. The VAS score ranges from 0 (no pain) to 10 (extreme unbearable pain) | immediately after injection |
Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
To evaluate the prognostic value of surem TRAF3IP2 levels in patients with acute myocardial infarction

Detailed Description
-----------------
Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients diagnosed with acute myocardial infarction who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the major adverse cardiac events will be evaluated.

Official Title
-----------------
Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction

Conditions
-----------------
Myocardial Infarction, Acute

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acute myocardial infarction patients received coronary angiography invasive management within 72 h of hospital admission Exclusion Criteria: NYHA III-IV malignant tumor acute infection thyroid dysfunction Life expectancy of b1 y Unsuitable for PCI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with acute myocardial infarction who experienced CAG<br>Patients with acute myocardial infarction who experienced coronary angiography | Other: No intervention<br>* This is an obvertional study, and there is no intervention.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACEs (major adverse cardiac events) | MACEs were defined as a composite of cardiac death, hospitalization for myocardial infarction or heart failure | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiac death | and death due to cardiac reasons, such as myocardial infarction or heart failure | 1 year | 
| hospitalization for myocardial infarction or heart failure | hospitalization for myocardial infarction or heart failure | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TRAF3IP2, Myocardial Infarction, Coronary angiography, MACEs
Place of Birth and Neonatal Health in Cases of Premature Birth Between 32 and 36 Weeks of Amenorrhoea

Study Overview
=================
Brief Summary
-----------------
Moderate and late premature babies (32-36 weeks of amenorrhoea) account for around 6% of births, but 20% of neonatal deaths. These children also have an increased risk of neonatal morbidity and long-term neurodevelopmental sequelae compared with full-term newborns. In the case of preterm birth, optimal antenatal, birth and postnatal management is necessary to prevent neonatal complications and mitigate longer-term consequences. However, we lack knowledge about the management of this at-risk population and the factors influencing their health. This knowledge is needed in the current context of unfavourable trends in neonatal health. Over the last ten years, neonatal and infant mortality has stagnated in France, with France falling behind other European countries. According to the latest European report, France ranks 22nd out of 33 countries. The causes of this stagnation are not well known, but many hypotheses have been put forward, including sub-optimal organisation of care.

Official Title
-----------------
Place of Birth and Neonatal Health in Cases of Preterm Birth Between 32 and 36 Weeks of Amenorrhoea: a National Population-based Study

Conditions
-----------------
Premature Between 32 and 36 Weeks of Amenorrhoea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All mothers and their newborn babies (live or stillborn) who had a delivery stay between 32 and 36 days of age recorded in the PMSI between 01/01/2015 and 31/12/2020. Exclusion Criteria: Births in very small maternity units Births in hospitals without an obstetrics unit Births outside hospitals.

Ages Eligible for Study
-----------------
Minimum Age: 0 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cohort<br>Mothers and their newborn babies (live or stillborn) who were delivered between 32 and 36 weeks' gestation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rate | Mortality (stillbirths, neonatal mortality before 28 days, hospital mortality) | up to 28 days after birth | 
| Neonatal morbidity rate | Neonatal morbidity. Composite indicator of neonatal morbidity defined by 18 ICD 10 and/or CCAM diagnostic codes and including the following sub-categories: respiratory, infectious, neurological, metabolic pathologies and obstetric trauma. | up to 28 days after birth |
Delving Into Participation Trends in Renal Cell Carcinoma Studies

Study Overview
=================
Brief Summary
-----------------
The study seeks to delve into the firsthand experiences of patients diagnosed with renal cell carcinoma who partake in a separate clinical study featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future renal cell carcinoma patients and play an active role in advancing clinical research.

Official Title
-----------------
Exploring Engagement Dynamics Among Individuals Impacted by Renal Cell Carcinoma

Conditions
-----------------
Renal Cell Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has been diagnosed with renal cell carcinoma Patient is a minimum of 18 years or older Patient has self-identified as planning to enroll in a clinical study Exclusion Criteria: Patient does not understand, sign, and return consent form Inability to perform regular electronic reporting Patient is pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to participate in a renal cell carcinoma clinical study |  | 3 months | 
| Rate of patients who remain in renal cell carcinoma clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Renal Cell Carcinoma
Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
This study is a multi-center, randomized, double-blind, parallel controlled phase 2 study, aimed at evaluating the efficacy and safety of CM310 in the treatment of patients with moderate-to-severe atopic dermatitis, and observing Pharmacokinetics characteristics, Pharmacodynamics effects and immunogenicity.

Detailed Description
-----------------
This study includes screening, treatment and follow-up periods. 160 subjects will be enrolled to receive CM310.

Official Title
-----------------
A Randomized, Double Blind, Parallel-controlled Phase 2 Study to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Subjects With Moderate-to-severe Atopic Dermatitis

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Biological: CM310


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have the ability to understand the study and voluntarily sign a written ICF. Age ≥ 18 and ≤ 75 years old, male or female. The fertile subjects agreed to take effective contraceptive measures throughout the study period. The subjects can communicate well with the investigators and complete the follow-up according to the protocol. Exclusion Criteria: Live vaccine or attenuated live vaccine has been vaccinated or planned to be vaccinated within 12 weeks before randomization. He received allergen-specific immunotherapy (desensitization therapy) within 6 months before randomization. Major surgery is planned during the study period. Previous history of atopic keratoconjunctivitis and corneal involvement. Other combined skin diseases that may affect the evaluation of the study. Confronting IL-4R α Monoclonal antibody or CM310/placebo drug or ingredient allergy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>CM310, subcutaneous | Biological: CM310<br>* IL-4Rα monoclonal antibody<br>|
| Experimental: Group B<br>CM310, subcutaneous | Biological: CM310<br>* IL-4Rα monoclonal antibody<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects achieving EASI-75 | Proportion of subjects achieving EASI-75 (≥75% reduction from baseline in Eczema Area and Severity Index score). | up to week 12 |
Comparison of MET vs Mobilization in Management of Post-partum Backache in Females (NVD) and Cesarean Section Delivery

Study Overview
=================
Brief Summary
-----------------
Effectiveness Comparison of Effects of Muscle Energy Technique (MET) vs Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery

Official Title
-----------------
Comparison of Effects of Muscle Energy Technique (MET) vs Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery

Conditions
-----------------
Cesarean Section Complications

Intervention / Treatment
-----------------
* Diagnostic Test: Mobilization
* Diagnostic Test: Muscle Energy Technique (MET)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with age group 20 to 40 year. low back pain and disability after normal vaginal delivery or c-section delivery will be included. Exclusion Criteria: Subjects who had neurological deficit. spinal tumors, scoliosis underwent spinal surgery prolapsed intervertebral disc with or without radiculopathy will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Muscle Energy Technique (MET)<br> | Diagnostic Test: Muscle Energy Technique (MET)<br>* Effects of Muscle Energy Technique (MET) in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery<br>|
| Other: Mobilization<br> | Diagnostic Test: Mobilization<br>* Effects of Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NPSR | Numeric pain rating scale | 6 Months | 
| Owestry | Owestry low back pain disability questionnaire | 6 Months |